M
1.14
0.02 (1.79%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | MAIA Biotechnology, Inc. | - | - |
AIStockmoo 评分
-1.1
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -1.13 |
|
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 23.33% |
| 机构持股比例 | 4.09% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Centric Wealth Management | 30 Jun 2026 | 796,723 |
| Bleakley Financial Group, Llc | 30 Jun 2026 | 181,623 |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合